CN Mobile Logo

Search form


Gastrointestinal Cancer

Gastrointestinal Cancer

Overweight individuals in early adulthood who gained additional weight to become obese later in life are at an increased risk for esophageal and gastric cardia adenocarcinomas.

The onset of diabetes or the rapid deterioration of existing diabetes may be an early signal for pancreatic cancer for some patients, according to the results of a study presented at the European Cancer Congress.

A study found that normal-weight women should be evaluated for metabolic health to reduce their risk for colorectal cancer.

Young and middle-aged patients diagnosed with colon cancer were more likely to receive postoperative chemotherapy compared with their older-age counterparts, according to the results from a recent cohort study.

Using immunohistochemistry to measure the expression of certain target enzymes—cox-2 and 15-prostaglandin dehydrogenase (15-PGDH)—in premalignant colorectal adenomas, researchers were able to get significant predictive and prognostic information in patients treated with the cox-2 inhibitor celecoxib for prevention of colorectal adenomas.

The addition of the BRAF inhibitor vemurafenib to irinotecan and cetuximab prolonged progression-free survival and resulted in a higher disease control rate than treatment with irinotecan and cetuximab alone in patients with BRAF-mutant metastatic colorectal cancer.

The immune checkpoint inhibitor nivolumab showed durable responses and disease control in a group of heavily pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer.


Subscribe to Gastrointestinal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.